drugset / Trial / NCT03114865
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Phase 1/2
Active not recruiting
44 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Amgen · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators primary objective is to determine the safety and toxicity of incorporating blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance setting for patients with CD19+-B-cell malignancies (Acute Lymphoblastic Leukemia \[ALL\], Non-Hodgkin's Lymphoma \[NHL\]).
Timeline
- Start
- 2017-09-05
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 28 ug | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |